RGNX · ISSUER CIK 1590877
REGENXBIO Inc.
Between Aug 1, 2026 and Oct 29, 2026, 5 REGENXBIO Inc. insiders reported $949K of open-market purchases and $0.00 of sales on SEC Form 4. The largest buyer was Ciongoli Gregory Austin (Director), with $949K.
↗5 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. No open-market sales in the window.
$949KInsider buying
$0.00Insider selling
+$949KNet open-market
Sep 3, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 202617:30 | Sep 1, 2026 | RGNX | Chief Technology Officer | F · Tax | $9.32 | −234 | 81,960 | -0% | $2K | ||
| Sep 3, 202617:29 | Sep 1, 2026 | RGNX | Chief Financial Officer | F · Tax | $9.32 | −4,902 | 122,815 | -4% | $46K | ||
| Aug 27, 202619:03 | Aug 27, 2026from Aug 26, 2026 | RGNX | Director | P · Buy | $9.25 | +102,603 | 118,035 | +665% | +$949K | -40.9% | -19.9% |
| Aug 27, 202619:03 | Aug 25, 2026 | RGNX | Director | A · Grant | — | +15,432 | 15,432 | New | — | ||
| Aug 4, 202616:30 | Aug 1, 2026 | RGNX | Chief Medical Officer | F · Tax | $9.69 | −7,468 | 205,541 | -4% | $72K | ||
| Aug 4, 202616:29 | Aug 1, 2026 | RGNX | Chief Strategy & Legal Officer | F · Tax | $9.69 | −4,699 | 205,968 | -2% | $46K |